DiagnoCure to present at Bloom Burton & Co. Healthcare Investor Conference on June 21, 2012
QUEBEC CITY, June 15, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced that the Company will present a review of its business strategy at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, June 21, 2012, at 9:30 AM (EDT). The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and European investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian public and private companies through presentations and break-out Q&A sessions. The conference is being held in Toronto on June 21, 2012.
More information on the Bloom Burton & Co. Healthcare Investor Conference 2012 can be found at www.bloomburton.com
About Bloom Burton & Co.
Bloom Burton & Co. is Canada's largest and most active healthcare-specialized investment banking group. The team of healthcare specialists merges scientific, medical, clinical, intellectual property and commercial expertise with a strong understanding of the capital markets, to advise and raise capital for private and public companies. For more information, please visit www.bloomburton.com.
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Company has also granted a worldwide exclusive license agreement to Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is now approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.Back to top